At Arcutis, we are focused on filling the innovation gap in medical dermatology drug development by leveraging our deep dermatology expertise and the latest advances in immunology and inflammation to develop best-in-class therapies against biologically validated targets.

Our Vision is to revitalize the standard of care for dermatological diseases and conditions through novel therapies that simplify disease management for physicians and eliminate the need to compromise between drug safety, efficacy and tolerability for patients.

The four novel products within Arcutis’ pipeline address large segments of the dermatology market and include topical roflumilast cream (ARQ-151) for plaque psoriasis and atopic dermatitis; topical roflumilast foam (ARQ-154) for seborrheic dermatitis and scalp psoriasis; ARQ-252 cream (JAK 1 inhibitor) for hand eczema and vitiligo; and ARQ-255, an alternative topical formulation of ARQ-252 for alopecia areata.

For more information, please visit: https://arcutis.com/bioscience-applied-to-the-skin/

Social Media Links:

https://www.linkedin.com/company/arcutis-inc/

https://twitter.com/ArcutisBio